Whipplewood Advisors LLC Buys 3,214 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Whipplewood Advisors LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 7,142.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,259 shares of the medical research company's stock after purchasing an additional 3,214 shares during the quarter. Whipplewood Advisors LLC's holdings in IQVIA were worth $575,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. grew its position in IQVIA by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after acquiring an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board increased its position in shares of IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after purchasing an additional 712,958 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of IQVIA by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock valued at $818,315,000 after buying an additional 77,981 shares in the last quarter. Invesco Ltd. lifted its position in IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after buying an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in IQVIA by 2.5% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock worth $481,380,000 after buying an additional 59,426 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 0.5%

IQV stock traded down $0.68 during trading on Thursday, hitting $147.22. 3,262,423 shares of the stock traded hands, compared to its average volume of 1,590,275. The firm's 50 day moving average is $148.65 and its two-hundred day moving average is $179.70. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market cap of $25.47 billion, a price-to-earnings ratio of 19.63, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. During the same period in the prior year, the firm posted $2.54 EPS. The firm's quarterly revenue was up 2.5% on a year-over-year basis. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on IQV shares. Wall Street Zen lowered shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Redburn Partners set a $188.00 price objective on IQVIA in a research note on Friday, May 23rd. Truist Financial decreased their target price on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Finally, Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.